We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-1.87%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.76B
AUM Growth
-$145M
Cap. Flow
-$29.4M
Cap. Flow %
-1.06%
Top 10 Hldgs %
57.66%
Holding
47
New
8
Increased
20
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$92.2M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$63.9M
3
MDT icon
Medtronic
MDT
+$52.8M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$52.7M
5
ZIMV
ZimVie
ZIMV
+$47.1M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.8M
2
MRK icon
Merck
MRK
+$78.8M
3
GSK icon
GSK
GSK
+$65.2M
4
BIIB icon
Biogen
BIIB
+$60M
5
WBA
Walgreens Boots Alliance
WBA
+$54.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.18%
2 Technology 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
26
Teva Pharmaceuticals
TEVA
$41.2B
$25.8M 0.93%
2,750,000
– –
INGN icon
27
Inogen
INGN
$164M
$24.3M 0.88%
750,000
+550,000
+275% +$17.3M
SEM
28
DELISTED
Select Medical
SEM
$24M 0.87%
+1,856,000
New +$24.5M
NKTR icon
29
Nektar Therapeutics
NKTR
$2.58B
$21.6M 0.78%
266,667
+16,667
+7% +$2.47M
COLL icon
30
Collegium Pharmaceutical
COLL
$956M
$21.4M 0.77%
1,050,000
– –
ZYME icon
31
Zymeworks
ZYME
$1.67B
$13.1M 0.47%
2,000,000
+1,200,000
+150% +$10.7M
PBYI icon
32
Puma Biotechnology
PBYI
$454M
$11.5M 0.42%
4,000,000
+1,950,000
+95% +$5.04M
GKOS icon
33
Glaukos
GKOS
$10.6B
$10.8M 0.39%
187,022
+112,022
+149% +$5.93M
EXEL icon
34
Exelixis
EXEL
$13.4B
$6.8M 0.25%
+300,000
New +$5.86M
EVH icon
35
Evolent Health
EVH
$447M
$5.99M 0.22%
+185,400
New +$4.85M
SDC
36
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$2.59M 0.09%
1,000,000
+575,000
+135% +$1.33M
RDUS
37
DELISTED
Radius Health, Inc.
RDUS
$2.32M 0.08%
+262,900
New +$1.99M
ALKS icon
38
Alkermes
ALKS
$8.25B
– –
-1,300,000
Closed -$30.2M
BIIB icon
39
Biogen
BIIB
$30.7B
– –
-250,000
Closed -$60M
INNV icon
40
InnovAge Holding
INNV
$1.52B
– –
-350,000
Closed -$1.75M
IRWD icon
41
Ironwood Pharmaceuticals
IRWD
$714M
– –
-3,000,000
Closed -$35M
MRK icon
42
CALL
Merck
MRK
$318B
– –
-2,000,000
Closed -$153M
NVS icon
43
CALL
Novartis
NVS
$297B
– –
-1,000,000
Closed -$87.5M
SNY icon
44
CALL
Sanofi
SNY
$104B
– –
-1,500,000
Closed -$75.2M
TBPH icon
45
Theravance Biopharma
TBPH
$877M
– –
-500,000
Closed -$5.53M
VRTX icon
46
Vertex Pharmaceuticals
VRTX
$126B
– –
-450,000
Closed -$98.8M
TECX
47
Tectonic Therapeutic
TECX
$606M
– –
-136,111
Closed -$6.29M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Camber Capital Management held 47 positions worth $2.76B, down 5% from $2.91B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Camber Capital Management's Q1 2022 filing shows 8 new, 20 increased, 5 reduced and 10 closed positions. Its largest new stake was Medtronic: 500,000 shares worth $55.5M. The largest sale was Vertex Pharmaceuticals, an estimated $98.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 86% a quarter earlier, followed by Technology.

  • Camber Capital Management's largest Q1 2022 buy was Medtronic: 500,000 shares worth $55.5M.
  • Camber Capital Management added most to Viatris in Q1 2022, an estimated $92.2M increase.
  • Camber Capital Management's biggest Q1 2022 reduction was Merck, cutting an estimated $78.8M.
  • Camber Capital Management fully exited Vertex Pharmaceuticals in Q1 2022, selling an estimated $98.8M.
  • Camber Capital Management's ten largest holdings make up 58% of its $2.76B portfolio in Q1 2022.
  • Camber Capital Management opened 8 new positions and closed 10 in Q1 2022.
  • Camber Capital Management's portfolio value fell 5% quarter-over-quarter to $2.76B.

Based on Camber Capital Management's 13F filing for Q1 2022, filed 16 May 2022.